KLOW peptide: four compounds, four mechanisms, one peer-reviewed record — printed here in four spot inks.

What Is KLOW Peptide?

KLOW peptide is a four-compound lyophilized research blend: BPC-157 (10 mg), TB-500 (10 mg), GHK-Cu (50 mg), and KPV (10 mg), totaling 80 mg per vial ^[25]. The formulation stacks four peptides whose preclinical records cover overlapping but mechanistically distinct research programs — angiogenesis and tissue repair (BPC-157), cell migration and wound closure (TB-500), collagen and extracellular matrix remodeling (GHK-Cu), and NF-kB-mediated inflammation control (KPV) ^{[1][7][11][14]}.

Each component has its own published literature. No controlled in-vivo study examines the four-peptide combination. What KLOW peptide represents in the research context is four independently studied mechanisms assembled into one preparation — four spot inks, each its own physical layer, overprinted on a single research page.

GHK-Cu at 50 mg is the mass-dominant component by a wide margin — five times the dose of each other peptide. Its role as the dominant ink is not arbitrary: GHK-Cu activates approximately 4,000 human genes relevant to tissue remodeling and collagen synthesis ^[11][12], making it the broadest genomic input in the blend.

BPC-157 at 10 mg contributes the angiogenesis and gut-protective arm. Across more than a decade of rodent studies, BPC-157 consistently upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling axis ^[1][2], accelerates tendon-to-bone healing ^[4][23], and demonstrates mucosal cytoprotection with clinical trial eligibility ^[5].

TB-500 at 10 mg delivers the actin-sequestration arm. Thymosin beta-4, the parent protein of the synthetic TB-500 fragment, drives cell migration and reepithelialization — 42% faster wound closure at day 4 and 61% by day 7 in rat wound models ^[8].

KPV at 10 mg is the NF-kB brake. This C-terminal tripeptide fragment of alpha-MSH blocks p65 RelA nuclear translocation via competitive inhibition of importin-alpha3, measurably reducing TNF-alpha-induced IL-8 secretion in bronchial epithelial cells ^[15] and cutting disease severity in murine colitis models at nanomolar concentrations ^[16].

The KLOW Peptide Blend: Four Compounds, One Protocol

The KLOW peptide blend is not a compound — it is a protocol in lyophilized form. Each peptide brings a different published mechanism to the same vial ^[25].

BPC-157 is a 15-amino-acid pentadecapeptide (1419.5 Da) isolated from human gastric juice. Its VEGFR2 upregulation and nitric oxide modulation have been reproduced across rat tendon, ligament, muscle, and gut injury models ^{[1][2][4][5][23]}. Three small human pilot studies — knee pain, interstitial cystitis, and pharmacokinetics — reported no adverse effects, though the compound remains investigational ^[19].

TB-500 is the synthetic Ac-LKKTETQ heptapeptide fragment of thymosin beta-4, the major actin-sequestering molecule in mammalian cells ^[7][9]. The full-length thymosin beta-4 protein has driven multicenter clinical trials for corneal and dermal wound repair ^[7]; TB-500 replicates the actin-binding, cell-migration, and anti-scarring activity at a fraction of the molecular weight ^[9].

GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II). Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[26]. In human fibroblast cultures, GHK-Cu stimulates collagen synthesis beginning at 10^-12 M and maximizing at 10^-9 M ^[10]. A 2025 study extended GHK-Cu's research applications into gut mucosal inflammation, showing SIRT1/STAT3 pathway modulation and restoration of tight junction proteins ZO-1 and Occludin in a murine colitis model [recent_1].

KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-MSH (342 Da). It retains the anti-inflammatory activity of the parent hormone without the pigmentation side effects ^[18]. Its transport via PepT1 into intestinal epithelial and immune cells is upregulated in inflamed colon tissue, which may enhance KPV uptake specifically at inflamed sites ^[16][17].

What Is the KLOW Blend?

The KLOW blend contains: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — 80 mg total per lyophilized vial ^[25]. The 50 mg GHK-Cu mass share means collagen and matrix biology drives the majority of the blend's weight. The three minority peptides bring complementary tissue-repair, angiogenic, and anti-inflammatory mechanisms.

Where KLOW diverges from the Wolverine stack (BPC-157 + TB-500 alone) is in the addition of GHK-Cu's genomic-scale matrix remodeling and KPV's hard NF-kB block. Where KLOW diverges from GLOW-type blends (which typically emphasize GHK-Cu + longevity peptides) is in BPC-157's gut and tendon repair profile and KPV's innate immune modulation ^[25].

No published preclinical or clinical study examines the four-peptide KLOW combination directly. The blend research context is built from the four individual literatures, extrapolated from complementary mechanisms rather than empirical co-administration data.

What Does the KLOW Peptide Do?

The KLOW peptide blend covers four mechanistic domains that individual-compound studies have characterized separately:

BPC-157 promotes angiogenesis through VEGFR2 upregulation, accelerates tendon-to-bone healing at 10 μg/kg/day in rats ^[4], and demonstrates gut mucosal cytoprotection that has reached clinical trial stage (PL 14736, Pliva, Croatia) ^[5]. A 2025 narrative review confirmed the VEGFR2/Akt-eNOS mechanism and classified the compound as investigational pending well-designed human trials ^[19].

TB-500 (the Ac-LKKTETQ fragment of thymosin beta-4) accelerates reepithelialization by 42% at day 4 and 61% at day 7 in rat wound models ^[8], reduces myofibroblast numbers to limit scar formation, and promotes new blood vessel formation across dermal, corneal, and cardiac models ^[7][9].

GHK-Cu modulates expression of approximately 4,000 human genes — 59% upregulated, 41% suppressed — including pathways for collagen synthesis, anti-inflammatory action, and COPD fibroblast restoration ^[12]. A collagen dressing containing GHK produced a 9-fold increase in collagen production in rats ^[12].

KPV rescued all animals from death during DSS colitis in mice lacking functional MC1R receptors, demonstrating an MC1R-independent mechanism ^[14]. Oral KPV reduced disease severity in both DSS- and TNBS-induced colitis models via PepT1-mediated uptake ^[16].

See the KLOW peptide benefits page for more on what each component's research record covers across specific tissue types.

What Is the KLOW Peptide Used For in Research?

Preclinical research on KLOW's four components covers several overlapping biological domains:

Tissue repair and angiogenesis. BPC-157 has accelerated Achilles tendon healing with improved biomechanical properties and collagen organization ^[4], medial collateral ligament healing over a 90-day study period in rats ^[23], and bone and muscle healing across multiple models ^[2]. TB-500 accelerates wound reepithelialization and reduces fibrosis ^[7][8].

Collagen and extracellular matrix remodeling. GHK-Cu is the dominant KLOW component by mass and the primary driver of collagen biology. GHK-Cu-liposomes shortened wound healing time to 14 days in a murine scald model with a 33.1% increase in cell proliferation and elevated VEGF and FGF-2 ^[13].

Gut and mucosal inflammation. BPC-157 has been studied in rodent IBD models at oral and intraperitoneal doses with anti-ulcer and mucosal healing results ^[5]. KPV at nanomolar oral concentrations reduced colitis severity in DSS and TNBS murine models ^[16]. A 2025 study showed GHK-Cu alleviates DSS-induced ulcerative colitis via SIRT1/STAT3 pathway modulation [recent_1].

Inflammatory modulation. KPV blocks NF-kB nuclear translocation at concentrations ≥ 1 μg/mL in bronchial epithelial cell cultures, reducing IL-8 secretion ^[15]. In murine IBD models, KPV-treated mice showed measurably reduced myeloperoxidase activity ^[14].

See how the four peptides work together and KLOW peptide dosage for the preclinical dose and route data.